- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05645718
Pedi-cRIB의 제2상 연구: 소아 B세포 계열 급성 림프구성 백혈병의 재발 치료를 위한 응축된 리툭시맙, 이노투주맙 오조가미신 및 블리나투모맙(cRIB)을 사용한 미니 하이퍼 CVD
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
연구 개요
상태
정황
상세 설명
Primary Objective:
--To evaluate the clinical efficacy of the sequential combination of mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab and rituximab in relapsed B-cell acute lymphoblastic leukemia (ALL) patients, based upon the complete response rate (CR).
Secondary Objectives:
- To summarize efficacy per response rate, overall survival (OS), event free survival (EFS), and minimal residual disease (MRD) negativity rate.
- To evaluate the safety of this combination.
Exploratory Objectives:
--To summarize associations between genomic alterations in ALL (current biomarker expression of the disease) with relation to the incidence of transition to HSCT in patients with PR or stable disease (SD) after the induction cycle(s).
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: David McCall, MD
- 전화번호: (713) 792-6604
- 이메일: dmccall1@mdanderson.org
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- M D Anderson Cancer Center
-
연락하다:
- David Mc Call, MD
- 전화번호: 713-792-6604
- 이메일: dmccall1@mdanderson.org
-
수석 연구원:
- David Mc Call, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Pediatric, adolescent, or young adult patients with B-ALL as per NCCN v2.2021 and WHO classification in relapse or primary refractory and, either/both of the following: • Unable to receive anthracyclines (see section 3.1.8) or is PEG-asparaginase intolerant.
- For leukemia: Patients must have ≥ 5% blasts expressing CD19 and CD22 in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood.
- If patient does not have CD20, they can still be enrolled but will not receive rituximab.
-
Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥ 50% for patients who are > 16 years old.
-
Patients with asymptomatic CNS leukemia are eligible (see also Exclusion Criterion 3.2.2.)
-
Age > = 1 years of age and less than 25 years of age.
-
The following baseline laboratory data:
- Total serum bilirubin ≤1.5x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN.
- Adequate renal function per age51 unless related to the disease. Estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults).
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement
-
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and 30 days after the last treatment and 8 months after the last dose of inotuzumab and 12 months after the last dose of rituximab. Effective methods of birth control include:
- Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin)
- Intrauterine devices (IUDs)
- Condom or occlusive cap (diaphragm or cervical/vault caps) used with Spermicide
- Abstinence
-
Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment and 5 months after the last dose of inotuzumab.
-
Patients with cardiac disease, include but not limited to: (Left ventricular ejection fraction (EF) < 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received >450mg/m2 of doxorubicin and cannot receive anthracyclines.
Exclusion Criteria:
-
Past or current history of a secondary or other primary tumor or a chronic myeloid leukemia (CML) blast crisis with exception of:
- Curatively treated non-melanomatous skin cancer
- Other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years
-
Presence of clinically significant uncontrolled CNS pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis. Presence of the following are allowed: headaches, vomiting, nerve palsy
-
Medical history of cardiovascular disease such as:
° Clinically significant cardiac disease including congestive heart failure (NYHA class III or IV) or arrhythmia or conduction abnormality requiring medication
-
Patients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable.
-
Known active hepatitis B or C infection or known seropositivity for HIV.
-
Patients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse.
-
Active acute/chronic Graft-versus-Host Disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.
-
If patient has not recovered (as deemed by the investigator) from previous chemotherapy, surgery, radiation before the start of study drugs.
° To reduce the circulating blast count or palliation, the following are allowed prior to starting: Single dose intravenous cytarabine, steroids or hydroxyurea. No washout necessary for these agents.
-
Females who are pregnant or lactating.
-
Male or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards.
-
Other severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated Protocol 2022-0312 V3 Dated 11/9/2023 Property of Leukemia at MD Anderson 17 with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study.
-
Patients with Trisomy 21, or bone marrow failure syndromes are not eligible.
-
Prior history of allergic reaction to any of the agents.
-
Patients who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.
-
Patients may be excluded if they are currently enrolled in another ongoing clinical trial with investigational products
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Leukemia CNS1 or 2
Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given. |
Given by (IV) vein
다른 이름들:
Given by (IV) vein Given by (IV) vein Given by (IV) vein Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by PO Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
|
|
실험적: Leukemia CNS 3
Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given. |
Given by (IV) vein
다른 이름들:
Given by (IV) vein Given by (IV) vein Given by (IV) vein Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by PO Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
Given by (IV) vein
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
부작용의 발생률, 국립 암 연구소 부작용에 대한 공통 용어 기준(NCI CTCAE) 버전(v) 5.0에 따라 등급이 매겨짐
기간: 연구 완료를 통해; 평균 1년.
|
연구 완료를 통해; 평균 1년.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: David McCall, MD, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 헴 및 림프병
- 백혈병
- 아미노산, 펩티드 및 단백질
- 단백질
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 탄화수소
- 탄화수소, 순환
- 탄수화물
- 알칼로이드
- 탄화수소, 방향족
- 다 환식 화합물
- 글리코 사이드
- 인돌
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 퓨린
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- 벤젠 유도체
- 설 폰산
- 황산
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- 뉴 클레오 시드
- Pterins
- Teridines
- Pregnadienetriols
- Pregnadienediols
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 아라비노 뉴 클레오 시드
- 아미노 테린
- 아미노 글리코 시드
- 항체, 모노클로 날, 뮤린 유래
- 벤젠 설포 네이트
- 아릴 설포 네이트
- 아릴 설 폰산
- 설페이드릴 화합물
- Calicheamicins
- 리툭시맙
- 이노투주맙 오조가미신
- 덱사메타손
- 메토트렉세이트
- 프레드니손
- 시클로포스파미드
- 시타라빈
- 빈크리스틴
- 메르캅토퓨린
- 칼슘 도베실레이트
- 블리나투모 맙
- Pegfilgrastim
- 페길화된 과립구 콜로니 자극 인자, 인간
기타 연구 ID 번호
- 2022-0312
- NCI-2022-10168 (기타 식별자: NCI-CTRP Clinical Trials Registry)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .